Apixaban Use Among Patients With Severe Renal Impairment

Annals of Pharmacotherapy

Volumn 48, Issue 12, 2014, Pages 1667-

  Deal, Eli N ^a   Pope, Hannah ^a   Ross, Will ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; ENOXAPARIN; EPTIFIBATIDE; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACUTE CORONARY SYNDROME; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DIALYSIS; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG INFORMATION; DRUG SAFETY; END STAGE RENAL DISEASE; EXERCISE; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; LETTER; LUNG EMBOLISM; PRIORITY JOURNAL; SEVERE RENAL IMPAIRMENT; DRUG LABELING; HUMAN; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY;

ANTICOAGULANTS; DRUG LABELING; HUMANS; KIDNEY FAILURE, CHRONIC; PYRAZOLES; PYRIDONES; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 84921483753     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014554446     Document Type: Letter

References (5)

1. Princeton, NJ: Bristol-Myers Squibb; 2014:
2. Granger CB,Alexander JH,McMurray JJ, et al.Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011;365:981-992
3. Agnelli G,Buller HR,Cohen A, et al.Oral apixaban for the treatment of acute venous thromboembolism.N Engl J Med. 2013;369:799-808
4. Wang X,Song Y,Tirucheraiet G, et al.Apixaban pharmaco-kinetics in subjects with end-stage renal disease on hemodialysis.Poster presented at: 2012 American College of Clinical Pharmacology Annual Meeting; San Diego, CA;.
5. Tsai TT,Maddox TM,Roe MT, et al.Contraindicated medication use in dialysis patients undergoing percutaneous coronary interventions.JAMA. 2009;302:2458-2464